PDF(Pubmed)
Abstract：
In this editorial, we comment on the article by Wang et al. This manuscript explores the potential synergistic effects of combining zanubrutinib, a novel oral inhibitor of Bruton\'s tyrosine kinase, with high-dose methotrexate (HD-MTX) as a therapeutic intervention for primary central nervous system lymphoma (PCNSL). The study involves a retrospective analysis of 19 PCNSL patients, highlighting clinicopathological characteristics, treatment outcomes, and genomic biomarkers. The results indicate the combination\'s good tolerance and strong antitumor activity, with an 84.2% overall response rate. The authors emphasize the potential of zanubrutinib to modulate key genomic features of PCNSL, particularly mutations in myeloid differentiation primary response 88 and cluster of differentiation 79B. Furthermore, the study investigates the role of circulating tumor DNA in cerebrospinal fluid for disease surveillance and treatment response monitoring. In essence, the study provides valuable insights into the potential of combining zanubrutinib with HD-MTX as a frontline therapeutic regimen for PCNSL. The findings underscore the importance of exploring alternative treatment modalities and monitoring genomic and liquid biopsy markers to optimize patient outcomes. While the findings suggest promise, the study\'s limitations should be considered, and further research is needed to establish the clinical relevance of this therapeutic approach for PCNSL.
摘要：
在这篇社论中，我们评论了Wang等人的文章。这篇手稿探讨了结合zanubrutinib的潜在协同效应，一种新型口服布鲁顿酪氨酸激酶抑制剂，大剂量甲氨蝶呤（HD-MTX）作为原发性中枢神经系统淋巴瘤（PCNSL）的治疗干预。该研究涉及对19例PCNSL患者的回顾性分析，突出临床病理特征，治疗结果，和基因组生物标志物。结果表明该组合具有良好的耐受性和较强的抗肿瘤活性,总反应率为84.2%。作者强调了扎努布替尼调节PCNSL关键基因组特征的潜力，特别是髓样分化初级反应88和分化簇79B中的突变。此外，本研究调查了脑脊液中循环肿瘤DNA在疾病监测和治疗反应监测中的作用.实质上,这项研究提供了有关扎努布替尼与HD-MTX联合作为PCNSL一线治疗方案的潜力的宝贵见解.研究结果强调了探索替代治疗方式以及监测基因组和液体活检标志物以优化患者预后的重要性。虽然研究结果表明有希望，应该考虑这项研究的局限性，需要进一步的研究来确定这种治疗方法与PCNSL的临床相关性。
